Bayforest Capital’s Janux Therapeutics JANX Stock Holding History

Bayforest Capital’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-3	Closed	-$42	–	1080
2026 Q1	$42	Buy	+3	New	+$41	﹤0.01%	875

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Bayforest Capital's JANX Position: Q2 2026 in Review

Bayforest Capital sold out of Janux Therapeutics (JANX) in Q2 2026, closing a stake of 3 shares — an estimated $42 sold.

Bayforest Capital first reported a position in JANX in Q1 2026 and held it in 1 quarter. The position peaked at $42 in Q1 2026. 198 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

Bayforest Capital reported no remaining Janux Therapeutics position as of Q2 2026 after selling out during the quarter.
Bayforest Capital sold 3 Janux Therapeutics shares in Q2 2026, an estimated $42.
Bayforest Capital first reported a position in Janux Therapeutics in Q1 2026 and held it in 1 quarter.
Bayforest Capital's Janux Therapeutics position peaked at $42 in Q1 2026.
198 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Bayforest Capital's 13F filing for Q2 2026, filed 5 Aug 2026.